BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Transcription profiling of mouse knock in mutant model for spinocerebellar ataxia type 1 and type 7 - symptomatic Sca1154Q/2Q and...

Dataset: Transcription profiling of mouse knock in mutant model for spinocerebellar ataxia type 1 and type 7 - symptomatic Sca1154Q/2Q and Sca7266Q/5Q cerebellum

Comparative analysis of cerebellar gene expression changes occurring in Sca1154Q/2Q and Sca7266Q/5Q knock-in mice; Polyglutamine diseases...

Registered by ArrayExpress Uploader
View Dataset

Comparative analysis of cerebellar gene expression changes occurring in Sca1154Q/2Q and Sca7266Q/5Q knock-in mice; Polyglutamine diseases are inherited neurodegenerative disorders caused by expansion of CAG repeats encoding a glutamine tract in the disease-causing proteins. There are nine disorders each having distinct features but also clinical and pathological similarities. In particular, spinocerebellar ataxia type 1 and type 7 (SCA1 and SCA7) patients manifest cerebellar ataxia with degeneration of Purkinje cells. To determine whether the disorders share molecular pathogenic events, we studied two mouse models of SCA1 and SCA7 that express the glutamine-expanded protein from the respective endogenous loci. We found common transcriptional changes, with down-regulation of Insulin-like growth factor binding protein 5 (Igfbp5) representing one of the most robust changes. Igfbp5 down-regulation occurred in granule neurons through a non-cell autonomous mechanism and was concomitant with activation of of the Insulin-like growth factor (IGF) pathway and the type I IGF receptor on Purkinje cells. These data define one common pathogenic response in SCA1 and SCA7 and reveal the importance of intercellular mechanisms in their pathogenesis. Given that SCA1 and SCA7 share a cerebellar degenerative phenotype, we proposed that some shared molecular changes might occur in both diseases, and that common molecular alterations could pinpoint pathways that could be targeted to modulate or monitor the pathogenesis of more than one disease. We focused on transcriptional changes because both ATXN1 and ATXN7 play roles in transcriptional regulation and transcriptional defects can be detected in early-symptomatic stages of both SCA1 and SCA7 mouse models. To test our hypothesis, we examined cerebellar gene expression patterns in SCA1 and SCA7 knock-in (KI) models--Sca1154Q/2Q and Sca7266Q/5Q mice. Experiment Overall Design: Total cerebellar RNA samples were collected from Sca1154Q/2Q knock-in and wild type mice at the early symptomatic disease stage (4 weeks, n=3 knock-in and 3 wild type; 9-12 weeks, n=3 knock-in and 3 wild type). In parallel experiments, total cerebellar RNA samples were collected from Sca7266Q/5Q knock-in and wild type mice also at the early symptomatic disease stage (5 weeks, n=5 knock-in and 5 wild type).

Species:
mouse

Samples:
22

Source:
E-GEOD-9914

PubMed:
18216249

Updated:
Dec.12, 2014

Registered:
Nov.24, 2014


Factors: (via ArrayExpress)
Sample AGE GENOTYPE
GSE9914GSM250857 4 SCA1 knock-in
GSE9914GSM250857 4 SCA1 knock-in
GSE9914GSM250857 4 SCA1 knock-in
GSE9914GSM250860 9 SCA1 knock-in
GSE9914GSM250861 12 SCA1 knock-in
GSE9914GSM250861 12 SCA1 knock-in
GSE9914GSM250863 4 SCA1 wild type
GSE9914GSM250863 4 SCA1 wild type
GSE9914GSM250863 4 SCA1 wild type
GSE9914GSM250866 9 SCA1 wild type
GSE9914GSM250867 12 SCA1 wild type
GSE9914GSM250867 12 SCA1 wild type
GSE9914GSM250869 5 SCA7 wild-type
GSE9914GSM250870 5 SCA7 knock-in
GSE9914GSM250870 5 SCA7 knock-in
GSE9914GSM250869 5 SCA7 wild-type
GSE9914GSM250870 5 SCA7 knock-in
GSE9914GSM250869 5 SCA7 wild-type
GSE9914GSM250869 5 SCA7 wild-type
GSE9914GSM250870 5 SCA7 knock-in
GSE9914GSM250869 5 SCA7 wild-type
GSE9914GSM250870 5 SCA7 knock-in

Tags

  • cell
  • cerebellar ataxia
  • disease
  • glutamine
  • insulin
  • protein
  • spinocerebellar ataxia
  • tract

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use